Key Insights Significant control over Kelington Group Berhad by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 8 investors have a majority stake in the company with 50% ownership Institutions own 34% of Kelington Group Berhad To get a sense of who is truly
Avalo Therapeutics Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Expected cash runway into 2027 WAYNE, Pa.
Guardion Health Sciences, Inc. Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical